Table 2. Summary of patient baseline characteristics according to patient follow-up status.
| LTFU | Transferred-out | Non-LTFU/transferred-out | |
|---|---|---|---|
| n = 182 | n = 56 | n = 596 | |
| Age (years) | |||
| Median (IQR) | 37.3 (31.7–43.8) | 37.0 (32.7–41.9) | 38.8 (32.5–46.3) |
| 15–30 years, n (%) | 43 (23.6) | 6 (10.7) | 94 (15.8) |
| 31–40 years, n (%) | 70 (38.5) | 32 (57.1) | 229 (38.4) |
| > 40 years, n (%) | 69 (37.9) | 18 (32.1) | 273 (45.8) |
| Gender | |||
| Male, n (%) | 84 (46.2) | 11 (19.6) | 225 (37.8) |
| Female, n (%) | 98 (53.8) | 45 (80.4) | 371 (62.2) |
| Body mass index (kg/m2) | |||
| Median (IQR) | 19.9 (18.3–21.8) | 18.7 (17.5–20.5) | 20.3 (18.3–22.7) |
| <18.5, n (%) | 50 (27.8) | 25 (44.7) | 156 (26.4) |
| 18.5–24.9, n (%) | 116 (64.4) | 27 (48.2) | 355 (60.2) |
| 25–29.9, n (%) | 10 (5.6) | 4 (7.1) | 65 (11) |
| ≥ 30, n (%) | 4 (2.2) | 0 | 14 (2.4) |
| eGFR (ml/min/1.73 m2) | |||
| Median (IQR) | 128.4 (117.4–137.6) | 128.4 (116.3–139.5) | 127.2 (113.0–138.1) |
| ≥ 60, n (%) | 163 (96.4) | 53 (96.4) | 561 (95.9) |
| < 60, n (%) | 6 (3.6) | 2 (3.6) | 24 (4.1) |
| African ethnicity, n (%) | 182 (100) | 56 (100) | 596 (100) |
| Smoking status | |||
| Non-smoker, n (%) | 158 (89.8) | 54 (96.4) | 547 (94.0) |
| Current smoker, n (%) | 18 (10.2) | 2 (3.6) | 35 (6.0) |
| Alcohol consumption | |||
| No, n (%) | 140 (79.5) | 47 (83.9) | 483 (83.0) |
| Yes, n (%) | 36 (20.5) | 9 (16.1) | 99 (17.0) |
| Tuberculosis comorbidity | |||
| No, n (%) | 156 (85.7) | 46 (82.1) | 521 (87.4) |
| Yes, n (%) | 26 (14.3) | 10 (17.9) | 75 (12.6) |
| CD4 count (cells/mm3) | |||
| Median (IQR) | 229 (44–438) | 137 (57–306) | 184 (71–343) |
| > 200, n (%) | 89 (53.0) | 21 (41.2) | 259 (46.3) |
| 50–200, n (%) | 36 (21.4) | 18 (35.3) | 204 (36.5) |
| < 50, n (%) | 43 (25.6) | 12 (23.5) | 96 (17.2) |
| WHO stage (I-IV) | |||
| I-II, n (%) | 75 (42.6) | 23 (41.8) | 300 (52.8) |
| III-IV, n (%) | 101 (57.4) | 32 (58.2) | 268 (47.2) |
| ART exposure during follow-up | |||
| ART-naive, n (%) | 85 (46.7) | 17 (30.4) | 102 (17.1) |
| ART-exposed, n (%) | 97 (53.3) | 39 (69.6) | 494 (82.9) |
| ART initiation regimen | |||
| AZT+3TC+NVP, n (%) | 1 (1.1) | 1 (2.6) | 7 (1.5) |
| AZT+3TC+EFV, n (%) | 9 (9.5) | 3 (7.9) | 44 (9.1) |
| TDF+FTC+EFV, n (%) | 34 (35.7) | 13 (34.2) | 150 (31.2) |
| TDF+3TC+EFV, n (%) | 46 (48.4) | 21 (55.3) | 275 (57.2) |
| ABC+3TC+EFV, n (%) | 2 (2.1) | 0 | 4 (0.8) |
| TDF+FTC+LPV/r, n (%) | 1 (1.1) | 0 | 1 (0.2) |
| TDF+FTC+ATV/r, n (%) | 2 (2.1) | 0 | 0 |
BMI: body mass index; eGFR: estimated glomerular filtration rate; n: number of patients; ART: antiretroviral therapy; AZT: zidovudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavirenz; TDF: tenofovir disoproxil fumarate; FTC: emtricitabine; ABC: abacavir; LPV/r: lopinavir/ritonavir; ATV/r: atazanavir/ritonavir. BMI: 8 missing values; eGFR: 25 missing values; smoking status: 20 missing values; alcohol consumption: 20 missing values; CD4 count: 56 missing values; WHO stage: 35 missing values; ART initiation regimen: 16 missing values;